Patient factors that may predispose to BRAF/MEK inhibitor–associated cardiotoxicity include pre-existing cardiovascular disease (prior heart failure/cardiomyopathy, ischemic heart disease, and severe valvular heart disease) as well as advancing age and other conventional cardiovascular risk factors such as hypertension, diabetes mellitus, chronic kidney disease, and cigarette smoking. This evidence concerns the gene BRAF and hypertensive disorder.